Proactive Investors - Run By Investors For Investors

Physiomics PLC: Personalised medicines will build on momentum from recent pharma deals

Jim MIllen, Physiomics Plc's chief executive, explains how the trend towards personalised medicines will aid the commercialisation of its virtual tumour software.

UK development agency Innovate has given the group two grants to help with research in the area.

That follows deals with two large pharmaceutical companies and a biotech this year for the cancer modelling software.

Physiomics had already announced a €500,000 contract with German group Merck Serono at the end of 2017.

 
Meet W Resources PLC, Avation PLC, Anglo Asian Mining PLC and Salt Lake Potash Ltd at our event, London , 28 February 2019. Register here »
View full PYC profile View Profile

Physiomics Plc Timeline

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use